Lung cancer treatment combo given initial NHS 'no' in England
A treatment combination has been provisionally rejected for people with certain types of lung cancer on the NHS in England.
Feb 12, 2019
0
0
A treatment combination has been provisionally rejected for people with certain types of lung cancer on the NHS in England.
Feb 12, 2019
0
0
Further evidence that immunotherapy provides long-term survival benefit for patients with lung cancer was presented today at ELCC 2018 (European Lung Cancer Congress) in Geneva, Switzerland.
Apr 12, 2018
0
7
(HealthDay)—For patients with metastatic renal cell carcinoma (mRCC), atezolizumab plus bevacizumab is associated with a progression-free survival benefit versus sunitinib, according to a study presented at the American ...
Feb 9, 2018
0
1
Some advanced lung cancer patients benefit from immunotherapy even after the disease has progressed as evaluated by standard criteria, according to research presented at the European Lung Cancer Conference (ELCC).1 The findings ...
May 5, 2017
0
0
A new immunotherapy drug, atezolizumab, has been approved for patients with metastatic urothelial carcinoma, a type of bladder cancer. The drug represents the first new treatment for this form of the disease in more than ...
Jun 1, 2016
0
115